CLEMENT CHRISTOPHER G 4
4 · DARA BioSciences, Inc. · Filed Jan 19, 2012
Insider Transaction Report
Form 4
CLEMENT CHRISTOPHER G
DirectorChief Operating Officer
Transactions
- Award
Common Stock
2012-01-17+215,661→ 215,661 total
Footnotes (2)
- [F1]Received in exchange for 4,420,156 shares of Oncogenerix, Inc. common stock in connection with the merger of Oncogenerix into a wholly-owned subsidiary of DARA Biosciences, Inc. (the "Merger"). The closing price of the common stock of DARA on the effective date of the Merger was $1.55. Of the 215,661 shares of DARA common stock received, 55,728 shares are currently being held in escrow and are subject to forfeiture during the 18-month period following the effective date of the Merger.
- [F2]The merger agreement to which Oncogenerix and DARA are parties provides that former stockholders of Oncogenerix will receive additional shares of DARA common stock if DARA achieves certain milestones during the 60 months following the effective date of the Merger. The reporting person's right to receive additional shares pursuant to the merger agreement became fixed and irrevocable on January 17, 2012, the effective date of the merger.